TERF2

Across TCGA pan-cancer cohorts, TERF2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TERF2 data layer compared with 17 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TERF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TERF2 expression acts as an unfavorable survival marker.

HNSC, COAD, and BLCA are the cancer types where TERF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.002	0.768	<.001	48	view →
COAD	OS	Median	II,III,IV	0.146	0.864	<.001	21	view →
BLCA	DFS	Median	All	0.100	0.626	<.001	9	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
SKCM	DFS	Median	III,IV	0.058	0.613	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TERF2–HNSC (OS)

Open the HNSC breakdown →